Catalog No.: PC-24082Not For Human Use, Lab Use Only.
JB170 is a potent, highly selective PROTAC degrader of Aurora A with DC50 of 28 nM and Dmax of 300 nM in MV4-11 cells, linking alisertib to the cereblon-binding molecule Thalidomide.
JB170 is a potent, highly selective PROTAC degrader of Aurora A with DC50 of 28 nM and Dmax of 300 nM in MV4-11 cells, linking alisertib to the cereblon-binding molecule Thalidomide. JB170 selectively binds AURORA-A (EC50=193 nM) over AURORA-B (EC50=1.4 µM). JB170 reduces AURORA-A levels by inducing proteolysis, induces AURORA-A ubiquitylation by CEREBLON followed by proteolysis via the proteasome. JB170 induces S-phase arrest in in MV4-11 cells, induces apoptosis in cancer cells.
